KR950703580A - CETP Inhibitor Polypeptide, Antibodies against the Synthetic Polypeptide and Prophylactic and Therapeutic AntiAtheroselerosis Treatments (CETP Inhibitor Polypeptide, Antibodies against the Synthetic Polypeptide) - Google Patents

CETP Inhibitor Polypeptide, Antibodies against the Synthetic Polypeptide and Prophylactic and Therapeutic AntiAtheroselerosis Treatments (CETP Inhibitor Polypeptide, Antibodies against the Synthetic Polypeptide) Download PDF

Info

Publication number
KR950703580A
KR950703580A KR1019950701273A KR19950701273A KR950703580A KR 950703580 A KR950703580 A KR 950703580A KR 1019950701273 A KR1019950701273 A KR 1019950701273A KR 19950701273 A KR19950701273 A KR 19950701273A KR 950703580 A KR950703580 A KR 950703580A
Authority
KR
South Korea
Prior art keywords
lys
glu
leu
ser
ala
Prior art date
Application number
KR1019950701273A
Other languages
Korean (ko)
Inventor
람프라탭 에스 쿠시와하
헨리 씨 쥬니어 맥길
패트릭 칸다
Original Assignee
프랭크 에프. 레드포드, 쥬니어
사우쓰웨스트 파운데이션 퍼 바이오메디칼 리써치
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 프랭크 에프. 레드포드, 쥬니어, 사우쓰웨스트 파운데이션 퍼 바이오메디칼 리써치 filed Critical 프랭크 에프. 레드포드, 쥬니어
Publication of KR950703580A publication Critical patent/KR950703580A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

폴리펩티드 및 그의 유사체는 콜레스테릴 에스테르 전달 단백질(CETP)를 억제한다. 항-아테롬성 동맥경화증 조성물은 항-아테롬성 동맥경화증 유효량의 폴리펩티드 및 제약학상 허용되는 담체로 이루어진다. 항-아테롬성 동맥경화증 키트는 별도의 멸균 용기 내의 폴리펩티드를 함유하는 적어도 1단위의 조성물. 1개의 주사기 및 1개의 바늘로 이루어진다. 항체는 본 발명의 폴리펩티드, 비비 CETP 4 kD 폴리펩티드 억제제, 아포 C-I, 변형된 아포 A-I(MW:31 kD) 또는 변형된 아포 E(MW:41 kD)의 1-36 아미노산 N-말단 단편에 대해 특이적이다. 본 발명의 예방 유효량의 폴리펩티드를 포유 동물에게 여하는 것으로 이루어지는, 아테롬성 동맥경화증에 걸리기 쉬운 포유 동물의 아테롬성 동맥경화증 예방법 및 본 발명의 치료 유효량의 폴리펩티드를 투여하는 것으로 이루어지는, 아테롬성 동맥경화증에 걸린 포유 동물의 아테롬성 동맥경화증 치료 방법이 제공된다.Polypeptides and analogs thereof inhibit cholesteryl ester transfer protein (CETP). The anti- atherosclerosis composition consists of an effective amount of anti- atherosclerotic arteriosclerosis and a pharmaceutically acceptable carrier. The anti- atherosclerosis kit is a composition of at least one unit containing the polypeptide in a separate sterile container. It consists of one syringe and one needle. The antibody is specific for a 1-36 amino acid N-terminal fragment of a polypeptide of the invention, a non-CETP 4 kD polypeptide inhibitor, apo CI, modified apo AI (MW: 31 kD) or modified apo E (MW: 41 kD). Enemy Mammals with atherosclerosis, comprising administering a prophylactically effective amount of a polypeptide of the invention to a mammal, comprising administering a method for preventing atherosclerosis in a mammal prone to atherosclerosis, and administering a therapeutically effective amount of a polypeptide of the invention A method for treating atherosclerosis of the present invention is provided.

Description

CETP 억제 폴리펩티드, 그 합성 폴리펩티드에 대한 항체 및 아테롬성 동맥 경화증의 예방학적 및 치료학적 처치(CETP Inhibitor Polypeptide, Antibodies against the Synthetic Polypeptide and Prophylactic and Therapeutic Anti-Atheroselerosis Treatments)CETP Inhibitor Polypeptide, Antibodies against the Synthetic Polypeptide and Prophylactic and Therapeutic Anti-Atheroselerosis Treatments

본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음Since this is an open matter, no full text was included.

Claims (18)

Ala-Pro-Asp-Val-Ser-Ser-Ala-Leu-Asp-Lys-Leu-Lys, Glu-Phe-Gly-Asn-Thr-Leu-Glu-Asp-Lys-Ala-Trp-Glu, Val-Ile-Asn-Arg-Ile-Lys-Gln-Ser-Glu-Phe-Pro-Ala-Lys-Thr(서열 번호 2) 및 Thr-Pro-Asp-Val-Ser-Ser-Ala-Leu-Asp-Lys-Leu-Lys, Glu-Phe-Gly-Asn-Thr-Leu-Glu-Asp-Lys-Ala-Arg-Glu, Leu-Ile-Ser-Arg-Ile-Lys-GIn-Ser-Glu-Leu-Ser-Ala-Lys-Met(서열 번호 3)으로 이루어진 군에서 선택된 펩티드의 적어도 일부로 이루어진 콜레스테릴 에스테르 전달 단백질의 억제 활성을 가진 실질적으로 순수한 폴리펩티드.Ala-Pro-Asp-Val-Ser-Ser-Ala-Leu-Asp-Lys-Leu-Lys, Glu-Phe-Gly-Asn-Thr-Leu-Glu-Asp-Lys-Ala-Trp-Glu, Val- Ile-Asn-Arg-Ile-Lys-Gln-Ser-Glu-Phe-Pro-Ala-Lys-Thr (SEQ ID NO: 2) and Thr-Pro-Asp-Val-Ser-Ser-Ala-Leu-Asp-Lys -Leu-Lys, Glu-Phe-Gly-Asn-Thr-Leu-Glu-Asp-Lys-Ala-Arg-Glu, Leu-Ile-Ser-Arg-Ile-Lys-GIn-Ser-Glu-Leu-Ser A substantially pure polypeptide having an inhibitory activity of a cholesteryl ester transfer protein consisting of at least a portion of a peptide selected from the group consisting of -Ala-Lys-Met (SEQ ID NO: 3). 제1항에 있어서, 동결 건조된 형태인 콜레스테릴 에스테르 전달 단백질 억제 폴리펩티드.The cholesteryl ester transfer protein inhibitory polypeptide according to claim 1, which is in lyophilized form. 항-아테롬성 동맥경화증 유효량의 Ala-Pro-Asp-Val-Ser-Ser-Ala-Leu-Asp-Lys-Leu-Lys, Glu-Phe-Gly-Asn-Thr-Leu-Glu-Asp-Lys-Ala-Trp-Glu, Val-Ile-Asn-Arg-Ile-Lys-Gln-Ser-Glu-Phe-Pro-Ala-Lys-Thr(서열 번호 2) 및 Thr-Pro-Asp-Val-Ser-Ser-Ala-Leu-Asp-Lys-Leu-Lys, Glu-Phe-Gly-Asn-Thr-Leu-Glu-Asp-Lys-Ala-Arg-Glu, Leu-Ile-Ser-Arg-Ile-Lys-Gin-Ser-Glu-Leu-Ser-Ala-Lys-Met(서열 번호 3)으로 이루어진 군에서 선택된 폴리펩티드의 적어도 일부 및 제약학상 허용되는 담체로 이루어진 항-아테롬성 동맥경화증 조성물.An effective amount of anti-atherogenic atherosclerosis Ala-Pro-Asp-Val-Ser-Ser-Ala-Leu-Asp-Lys-Leu-Lys, Glu-Phe-Gly-Asn-Thr-Leu-Glu-Asp-Lys-Ala -Trp-Glu, Val-Ile-Asn-Arg-Ile-Lys-Gln-Ser-Glu-Phe-Pro-Ala-Lys-Thr (SEQ ID NO: 2) and Thr-Pro-Asp-Val-Ser-Ser- Ala-Leu-Asp-Lys-Leu-Lys, Glu-Phe-Gly-Asn-Thr-Leu-Glu-Asp-Lys-Ala-Arg-Glu, Leu-Ile-Ser-Arg-Ile-Lys-Gin- An anti-atherosclerotic composition comprising at least a portion of a polypeptide selected from the group consisting of Ser-Glu-Leu-Ser-Ala-Lys-Met (SEQ ID NO: 3) and a pharmaceutically acceptable carrier. 별도의 멸균 용기 내의 제3항의 조성물 적어도 10내지 400mg, 1개 이상의 주사기 및 1개 이상의 바늘로 이루어진 항-아테롬성 동맥경화증 키트.The anti-atherosclerotic kit comprising at least 10 to 400 mg of the composition of claim 3 in a separate sterile container, at least one syringe and at least one needle. Ala-Pro-Asp-Val-Ser-Ser-Ala-Leu-Asp-Lys-Leu-Lys, Glu-Phe-Gly-Asn-Thr-Leu-Glu-Asp-Lys-Ala-Trp-Glu, Val-Ile-Asn-Arg-Ile-Lys-Gln-Ser-Glu-Phe-Pro-Ala-Lys-Thr(서열 번호 2) 및 Thr-Pro-Asp-Val-Ser-Ser-Ala-Leu-Asp-Lys-Leu-Lys, Glu-Phe-Gly-Asn-Thr-Leu-Glu-Asp-Lys-Ala-Arg-Glu, Leu-Ile-Ser-Arg-Ile-Lys-Gin-Ser-Glu-Leu-Ser-Ala-Lys-Met(서열 번호 3)으로 이루어진 군에서 선택된 폴리펩티드의 적어도 일부로 이루어진 폴리펩티드에 대해 특이적인 항체.Ala-Pro-Asp-Val-Ser-Ser-Ala-Leu-Asp-Lys-Leu-Lys, Glu-Phe-Gly-Asn-Thr-Leu-Glu-Asp-Lys-Ala-Trp-Glu, Val- Ile-Asn-Arg-Ile-Lys-Gln-Ser-Glu-Phe-Pro-Ala-Lys-Thr (SEQ ID NO: 2) and Thr-Pro-Asp-Val-Ser-Ser-Ala-Leu-Asp-Lys -Leu-Lys, Glu-Phe-Gly-Asn-Thr-Leu-Glu-Asp-Lys-Ala-Arg-Glu, Leu-Ile-Ser-Arg-Ile-Lys-Gin-Ser-Glu-Leu-Ser An antibody specific for a polypeptide consisting of at least a portion of a polypeptide selected from the group consisting of -Ala-Lys-Met (SEQ ID NO: 3). 제5항에 있어서, 폴리클로날 항체인 항체.The antibody of claim 5 which is a polyclonal antibody. 제5항에 있어서, 변형된 아포 A-I에 특이적으로 결합할 수 있는 항체.The antibody of claim 5, wherein the antibody can specifically bind to modified apo A-I. 제5항에 있어서, 비비 CETP억제 폴리펩티드에 특이적으로 결합할 수 있는 항체.The antibody of claim 5, wherein the antibody can specifically bind to a non-non-CETP inhibitory polypeptide. 제5항에 있어서, 변형된 아포 E에 특이적으로 결합할 수 있는 항체.The antibody of claim 5, which is able to specifically bind to modified Apo E. 7. 제5항에 있어서, 아포 C-I에 특이적으로 결합할 수 있는 항체.The antibody of claim 5, wherein the antibody can specifically bind Apo C-I. Ala-Pro-Asp-Val-Ser-Ser-Ala-Leu-Asp-Lys-Leu-Lys, Glu-Phe-Gly-Asn-Thr-Leu-Glu-Asp-Lys-Ala-Trp-Glu, Val-Ile-Asn-Arg-Ile-Lys-Gln-Ser-Glu-Phe-Pro-Ala-Lys-Thr(서열 번호 2) 및 Thr-Pro-Asp-Val-Ser-Ser-Ala-Leu-Asp-Lys-Leu-Lys, Glu-Phe-Gly-Asn-Thr-Leu-Glu-Asp-Lys-Ala-Arg-Glu, Leu-Ile-Ser-Arg-Ile-Lys-Gin-Ser-Glu-Leu-Ser-Ala-Lys-Met(서열 번호 3)으로 이루어진 군에서 선택된 펩티드의 적어도 일부로 이루어진 예방 유효량의 폴리펩티드를 아테롬성 동맥경화증에 걸리기 쉬운 포유 동물에게 투여하는 것으로 이루어지는, 아테롬성 동맥경화증에 걸리기 쉬운 포유 동물의 아테롬성 동맥경화증 예방법.Ala-Pro-Asp-Val-Ser-Ser-Ala-Leu-Asp-Lys-Leu-Lys, Glu-Phe-Gly-Asn-Thr-Leu-Glu-Asp-Lys-Ala-Trp-Glu, Val- Ile-Asn-Arg-Ile-Lys-Gln-Ser-Glu-Phe-Pro-Ala-Lys-Thr (SEQ ID NO: 2) and Thr-Pro-Asp-Val-Ser-Ser-Ala-Leu-Asp-Lys -Leu-Lys, Glu-Phe-Gly-Asn-Thr-Leu-Glu-Asp-Lys-Ala-Arg-Glu, Leu-Ile-Ser-Arg-Ile-Lys-Gin-Ser-Glu-Leu-Ser Atherosclerosis susceptible to atherosclerosis, comprising administering a prophylactically effective amount of a polypeptide consisting of at least a portion of a peptide selected from the group consisting of -Ala-Lys-Met (SEQ ID NO: 3) to a mammal susceptible to atherosclerosis Atherosclerosis prophylaxis. 제11항에 있어서, 폴리펩티드가 약 10 내지 200mg의 양으로 투여되는 방법.The method of claim 11, wherein the polypeptide is administered in an amount of about 10 to 200 mg. 제22항에 있어서, 폴리펩티드가 정맥내로 투여되는 방법.The method of claim 22, wherein the polypeptide is administered intravenously. 제22항에 있어서, 포유 동물의 인간인 방법.The method of claim 22, wherein the mammal is a human. Ala-Pro-Asp-Val-Ser-Ser-Ala-Leu-Asp-Lys-Leu-Lys, Glu-Phe-Gly-Asn-Thr-Leu-Glu-Asp-Lys-Ala-Trp-Glu, Val-Ile-Asn-Arg-Ile-Lys-Gln-Ser-Glu-Phe-Pro-Ala-Lys-Thr(서열 번호 2) 및 Thr-Pro-Asp-Val-Ser-Ser-Ala-Leu-Asp-Lys-Leu-Lys, Glu-Phe-Gly-Asn-Thr-Leu-Glu-Asp-Lys-Ala-Arg-Glu, Leu-Ile-Ser-Arg-Ile-Lys-GIn-Ser-Glu-Leu-Ser-Ala-Lys-Met(서열 번호 3)으로 이루어진 군에서 선택된 펩티드의 적어도 일부로 이루어진 치료 유혀량의 폴리펩티드를 아테롬성 동맥경화증에 걸린 포유 동물에게 투여하는 것으로 이루어지는, 아테롬성 동맥경화증에 걸린 포유 동물의 아롬성 동맥경화증 치료방법.Ala-Pro-Asp-Val-Ser-Ser-Ala-Leu-Asp-Lys-Leu-Lys, Glu-Phe-Gly-Asn-Thr-Leu-Glu-Asp-Lys-Ala-Trp-Glu, Val- Ile-Asn-Arg-Ile-Lys-Gln-Ser-Glu-Phe-Pro-Ala-Lys-Thr (SEQ ID NO: 2) and Thr-Pro-Asp-Val-Ser-Ser-Ala-Leu-Asp-Lys -Leu-Lys, Glu-Phe-Gly-Asn-Thr-Leu-Glu-Asp-Lys-Ala-Arg-Glu, Leu-Ile-Ser-Arg-Ile-Lys-GIn-Ser-Glu-Leu-Ser Aromes of mammals with atherosclerosis, comprising administering to a mammal with atherosclerosis a therapeutically plentiful amount of polypeptide consisting of at least a portion of a peptide selected from the group consisting of -Ala-Lys-Met (SEQ ID NO: 3). How to treat atherosclerosis. 제15항에 있어서, 폴리펩티드가 약 10내지 400mg의 양으로 투여되는 치료방법.The method of claim 15, wherein the polypeptide is administered in an amount of about 10 to 400 mg. 제15항에 있어서, 폴리펩티드가 정맥내로 투여되는 방법.The method of claim 15, wherein the polypeptide is administered intravenously. 제15항에 있어서, 포유 동물이 인간인 방법.The method of claim 15, wherein the mammal is a human. ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.※ Note: The disclosure is based on the initial application.
KR1019950701273A 1993-08-04 1994-08-02 CETP Inhibitor Polypeptide, Antibodies against the Synthetic Polypeptide and Prophylactic and Therapeutic AntiAtheroselerosis Treatments (CETP Inhibitor Polypeptide, Antibodies against the Synthetic Polypeptide) KR950703580A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10216093A 1993-08-04 1993-08-04
US08/102160 1993-08-04
PCT/US1994/008624 WO1995004755A1 (en) 1993-08-04 1994-08-02 Cetp inhibitor polypeptide, antibodies against the synthetic polypeptide and prophylactic and therapeutic anti-atherosclerosis treatments

Publications (1)

Publication Number Publication Date
KR950703580A true KR950703580A (en) 1995-09-20

Family

ID=22288420

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019950701273A KR950703580A (en) 1993-08-04 1994-08-02 CETP Inhibitor Polypeptide, Antibodies against the Synthetic Polypeptide and Prophylactic and Therapeutic AntiAtheroselerosis Treatments (CETP Inhibitor Polypeptide, Antibodies against the Synthetic Polypeptide)

Country Status (6)

Country Link
EP (1) EP0664813A4 (en)
JP (1) JPH08502525A (en)
KR (1) KR950703580A (en)
AU (1) AU683295B2 (en)
CA (1) CA2145767A1 (en)
WO (1) WO1995004755A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0831881B1 (en) * 1995-06-06 2003-03-12 Avant Immunotherapeutics, Inc. Cetp for increasing hdl cholesterol level
US20130156720A1 (en) 2010-08-27 2013-06-20 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4904481A (en) * 1985-04-17 1990-02-27 The Board Of Trustess Of Leland Stanford University Method of conferring immuno-tolerance to a specific antigen
EP0618803A4 (en) * 1991-12-19 1995-03-22 Southwest Found Biomed Res Cetp inhibitor polypeptide, antibodies against the synthetic polypeptide and prophylactic and therapeutic anti-atherosclerosis treatments.

Also Published As

Publication number Publication date
AU683295B2 (en) 1997-11-06
JPH08502525A (en) 1996-03-19
AU7552694A (en) 1995-02-28
WO1995004755A1 (en) 1995-02-16
EP0664813A4 (en) 1998-05-27
EP0664813A1 (en) 1995-08-02
CA2145767A1 (en) 1995-02-16

Similar Documents

Publication Publication Date Title
EP0477295B2 (en) Platelet aggregation inhibitors
US5935926A (en) Platelet aggregation inhibitors
US7094760B2 (en) Peptides for treatment of inflammation and shock
EP2327712A3 (en) Treatment of autoimmune conditions with copolymer 1 and related copolymers and peptides
CA2155303A1 (en) Treatment for insulin dependent diabetes
KR950701818A (en) DES-TYR DYNORPHIN ANALOGUES
JPH06504765A (en) Novel antithrombotic substance
RU97105374A (en) MODIFIED PROTEINS
CA2053799C (en) Synthetic peptide specificity of anti-myelin basic protein from multiple sclerosis cerebrospinal fluid
US3864481A (en) Anti disease producing synthetic material for the prevention suppression and diagnosis of multiple sclerosis and method of treatment therefor
Timpl et al. Characterization of conformation independent antigenic determinants in the triple-helical part of calf and rat collagen
Bidart et al. Antigenic determinants on human choriogonadotropin alpha-subunit. I. Characterization of topographic sites recognized by monoclonal antibodies.
AU679913B2 (en) Stable polypeptide composition
US5344783A (en) Platelet aggregation inhibitors
KR950703580A (en) CETP Inhibitor Polypeptide, Antibodies against the Synthetic Polypeptide and Prophylactic and Therapeutic AntiAtheroselerosis Treatments (CETP Inhibitor Polypeptide, Antibodies against the Synthetic Polypeptide)
Gregerson et al. Preparation, isolation, and immunochemical studies of the cyanogen bromide peptides from a retinal photoreceptor cell autoantigen, S-antigen.
Shohet et al. Localization of the human complement component C3 binding site on the IgG heavy chain.
US5514775A (en) Chromogranin peptides
NZ324100A (en) Luminal cholecystokinin-releasing factor
WO1997015671A9 (en) Luminal cholecystokinin-releasing factor
Benson et al. Amino terminal sequence of amyloid P-component isolated from serum
ITMI20011833A1 (en) AGENTS REGULATING VASCULAR PERMEABILITY
AU708857C (en) Luminal cholecystokinin-releasing factor
Matsumoto et al. Structural Studies of Another Human IgG3 Myeloma Protein (Kam) Carrying the Allotypic Markers Gm (s, t) and Its Alterration Induced by Chemical Modification
AU636159C (en) Platelet aggregation inhibitors

Legal Events

Date Code Title Description
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid